Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
3.110
-0.310 (-9.06%)
Nov 20, 2026, 4:00 PM EST - Market closed
Immutep Revenue
In the fiscal year ending June 30, 2026, Immutep had annual revenue of 14.60M AUD with 24,344.44% growth. Immutep had revenue of 10.50M in the half year ending June 30, 2026, with 34,682.21% growth.
Revenue (ttm)
14.60M AUD
Revenue Growth
+24,344.44%
P/S Ratio
1.70
Revenue / Employee
470,824 AUD
Employees
31
Market Cap
23.50M USD
Revenue by Segment
- Immunotherapy 5.03M 99.8%
- Unallocated 9.24K 0.2%
Fiscal year ended Jun 30, 2025 See the full Immutep breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 14.60M | 14.54M | 24,344.44% |
| Jun 30, 2025 | 59.71K | -59.38K | -49.86% |
| Jun 30, 2024 | 119.09K | -72.63K | -37.88% |
| Jun 30, 2023 | 191.72K | -62.67K | -24.63% |
| Jun 30, 2022 | 254.39K | -58.45K | -18.68% |
| Jun 30, 2021 | 312.84K | -7.45M | -95.97% |
| Jun 30, 2020 | 7.77M | 6.47M | 499.78% |
| Jun 30, 2019 | 1.29M | -2.34M | -64.42% |
| Jun 30, 2018 | 3.64M | 2.84M | 354.63% |
| Jun 30, 2017 | 800.46K | 625.41K | 357.27% |
| Jun 30, 2016 | 175.05K | - | - |
| Jun 30, 2015 | - | - | - |
| Jun 30, 2014 | - | - | - |
| Jun 30, 2013 | - | - | - |
| Jun 30, 2012 | - | - | - |
| Jun 30, 2011 | - | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | - | - | - |
| Jun 30, 2008 | - | - | - |
| Jun 30, 2007 | - | - | - |
| Jun 30, 2006 | - | - | - |
| Jun 30, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
IMMP News
- 1 day ago - Immutep Limited Reports 81.1% 12-month Disease-Free Survival in EFTISARC-NEO Phase II Trial - Nasdaq
- 2 days ago - Immutep Posts New Survival Data From Phase 2 EFTISARC-NEO Trial;Stock Up - Nasdaq
- 2 days ago - Immutep Transcript: Bell Potter Healthcare Conference - Transcripts
- 2 days ago - Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma - GlobeNewsWire
- 10 days ago - Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies - GlobeNewsWire
- 10 days ago - Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO - GlobeNewsWire
- 12 days ago - Immutep Limited - Depositary Receipt Price Target Increased by 19.55% to $80.11 - Nasdaq
- 12 days ago - Immutep announces data from its Phase I study of IMP761 - TheFly